Ann: DEP HER2-lutetium outperforms in human breast cancer model, page-3

While another great result, let's just focus on getting one DEP product licensed ?  I see the billions of $ of potential have been thrown around in the announcement again - our CEO loves to promote the $bn potentials  ... hehe



Melbourne, Australia; 16 March 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its second radiopharmaceutical candidate, DEP® HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin® (trastuzumab) labelled with lutetium, in a human breast cancer model (BT474).

Radiotheranostics is a rapidly developing area of cancer treatment and diagnosis, which has recently generated several high-value deals and sales in this category are estimated to grow to $12–15 billion by 2030. 2 Recent deals include the acquisition of Endocyte by Novartis for US$2.1 billion and the acquisition of Sirtex by CDH Genetech for ~A$1.9 billion.

Worldwide, breast cancer is the most common cancer in women and the second most common cancer in the US. HER2 (human epidermal growth factor receptor 2) is a growthpromoting protein on the outside of all breast cells. Breast cancer cells with higher-thannormal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than other breast cancers but are much more likely to respond to treatments with drugs that target the HER2 protein (such as Herceptin®.3

The HER2 receptor also exists in some other cancers such as gastric, colon, bladder and biliary cancers. HER2 cancer treatments include Roche’s Herceptin® and Perjeta® with sales of approximately US$7 billion and US$4 billion respectively.